Functional genetic polymorphisms from phase-ii drug metabolizing enzymes

CNS Neuroscience and Therapeutics

Volumn 18, Issue 8, 2012, Pages 705-706

  Grover, Sandeep ^a   Kukreti, Ritushree ^a  

^a CSIR INSTITUTE OF GENOMICS AND INTEGRATIVE BIOLOGY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; DRUG METABOLIZING ENZYME; PHENYTOIN;

DRUG RESPONSE; EPILEPSY; GENE FREQUENCY; GENE INTERACTION; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; LETTER; PHARMACOGENOMICS;

EID: 84864772299     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/j.1755-5949.2012.00343.x     Document Type: Letter

References (7)

1. Murali M, Manjari T, Madhuri B, et al. Genetic polymorphism of NAT2 metabolizing enzymes on phenytoin pharmacokinetics in Indian epileptic patients developing toxicity. CNS Neurosci Ther 2012;18:350-358.
2. Grover S, Gourie-Devi M, Baghel R, et al. Genetic profile of patients with epilepsy on first-line antiepileptic drugs and potential directions for personalized treatment. Pharmacogenomics 2010;11:927-941.
3. Grant DM, Hughes NC, Janezic SA, et al. Human acetyltransferase polymorphisms. Mutat Res 1997;376:61-70.
4. Indian Genome Variation Consortium. Genetic landscape of the people of India: A canvas for disease gene exploration. J Genet 2008;87:3-20.
5. Arif E, Vibhuti A, Alam P, et al. Association of CYP2E1 and NAT2 gene polymorphisms with chronic obstructive pulmonary disease. Clin Chim Acta 2007;382:37-42.
6. Hung CC, Chang WL, Ho JL, et al. Association of polymorphisms in EPHX1, UGT2B7, ABCB1, ABCC2, SCN1A and SCN2A genes with carbamazepine therapy optimization. Pharmacogenomics. 2012;13:159-169.
7. Grover S, Gupta M, Kukreti R. Challenges and recommendations for conducting epidemiological studies in the field of epilepsy pharmacogenetics. Indian J Hum Genet 2011;17:4-11.